IMMUNOBIOLOGICAL AGENT AND A METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO THE MIDDLE EASTERN RESPIRATORY SYNDROME VIRUS (VERSIONS) Russian patent published in 2019 - IPC C12N15/00 A61K39/215 

FIELD: biotechnology.

SUBSTANCE: invention refers to biotechnology, immunology and virology. Described is an immunobiological agent based on human recombinant adenovirus 5-th serotype or recombinant human adenovirus 26-th serotype, containing optimized expression in mammal cells consensus sequence of complete protective antigen S of MERS virus on the basis of sequences of protein S genes of modern strains of virus MERS 2015–2017 years with sequence SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5. Method for using the immunobiological agent for inducing specific immunity to MERS-CoV. Method of using the immunobiological agent consists in the sequential introduction into the body of mammals of two different immunobiological agents based on human recombinant adenovirus of 5-th serotype or two different immunobiological agents based on human recombinant adenovirus of 26-th serotype with a period of more than 1 week, for inducing specific immunity to MERS-CoV. There is also developed a method for using the immunobiological agent consisting in consecutive introduction into an organism of mammals of any of the immunobiological agents based on human recombinant adenovirus of 5-th serotype and any of the immunobiological preparations based on human recombinant adenovirus 26-th serotype with a period of more than 1 week, for the induction of specific immunity to MERS-CoV, or in consecutive introduction into organism of mammals of any of immunobiological agents on the basis of recombinant human adenovirus of 26-th serotype and any of immunobiological agents on the basis of recombinant human adenovirus of 5-th serotype with interval of more than 1 week, for induction of specific immunity to MERS-CoV. There is also developed a method for using an immunobiological agent consisting in simultaneous introduction into an organism of mammals of any two immunobiological agents on the basis of recombinant human adenovirus of 5-th serotype for induction of specific immunity to BVRS-CoV.

EFFECT: presented agent can be used for prevention of Middle Eastern respiratory syndrome.

9 cl, 7 dwg, 8 tbl, 13 ex